Business
Blue Water Vaccines Inc. to Present at H.C. Wainwright Global Investment Conference
CINCINNATI, May 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing
About this update from Onconetix, Inc.
[{"type":"text","content":"CINCINNATI, May 12, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”) a biopharmaceutical company developing transformational vaccines to address significant global health challenges, today announced that Erin Henderson, Chief Business Officer of Blue Water Vaccines, will present at the H.C. Wainwright Global Investment Conference. The presentation will be available for on-demand webcast viewing starting on Wednesday, May 25, 2022, at 9:00am EDT. Session details are as follows Date:Wednesday, May 25, 2022Time:9:00am Eastern Daylight Time (EDT)Title:Blue Water Vaccines Company PresentationBWV Participant:Erin Henderson, Chief Business OfficerWebcast Link: https://journey.ct.events/view/1e8775a5-ce07-4395-867a-0cadcc5664e5 BWV’s management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting at [email protected] or contact BWV at (513) 620-4101. About Blue Water Vaccines Blue Water Vaccines Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital. The company is developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria, among others. Additionally, Blue Water Vaccines is developing a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. For more information, visit www.bluewatervaccines.com. Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking s...